[go: up one dir, main page]

BRPI0917083A2 - compostos com efeito de agitação no recptor de subtipo delta ativado por proliferador de peroxissomo, processo para sua preparação e uso destes - Google Patents

compostos com efeito de agitação no recptor de subtipo delta ativado por proliferador de peroxissomo, processo para sua preparação e uso destes

Info

Publication number
BRPI0917083A2
BRPI0917083A2 BRPI0917083A BRPI0917083A BRPI0917083A2 BR PI0917083 A2 BRPI0917083 A2 BR PI0917083A2 BR PI0917083 A BRPI0917083 A BR PI0917083A BR PI0917083 A BRPI0917083 A BR PI0917083A BR PI0917083 A2 BRPI0917083 A2 BR PI0917083A2
Authority
BR
Brazil
Prior art keywords
compounds
preparation
peroxisome proliferator
agitation effect
subtype receptor
Prior art date
Application number
BRPI0917083A
Other languages
English (en)
Inventor
Chunhua Jin
Shoufeng Ming
Xiaohe Zheng
Xiaoyu Liu
Zhenliang Chen
Original Assignee
Zhejiang Hisun Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharm Co Ltd filed Critical Zhejiang Hisun Pharm Co Ltd
Publication of BRPI0917083A2 publication Critical patent/BRPI0917083A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0917083A 2008-08-07 2009-08-07 compostos com efeito de agitação no recptor de subtipo delta ativado por proliferador de peroxissomo, processo para sua preparação e uso destes BRPI0917083A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2008101473100A CN101643451B (zh) 2008-08-07 2008-08-07 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
PCT/CN2009/073140 WO2010015212A1 (zh) 2008-08-07 2009-08-07 一种对δ亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用

Publications (1)

Publication Number Publication Date
BRPI0917083A2 true BRPI0917083A2 (pt) 2016-06-14

Family

ID=41655537

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917083A BRPI0917083A2 (pt) 2008-08-07 2009-08-07 compostos com efeito de agitação no recptor de subtipo delta ativado por proliferador de peroxissomo, processo para sua preparação e uso destes

Country Status (8)

Country Link
US (1) US8822519B2 (pt)
EP (1) EP2330098B1 (pt)
JP (1) JP5710480B2 (pt)
KR (1) KR101662592B1 (pt)
CN (2) CN101643451B (pt)
BR (1) BRPI0917083A2 (pt)
RU (1) RU2522450C2 (pt)
WO (1) WO2010015212A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
AU2011258009B2 (en) * 2010-05-28 2016-04-21 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
JP6404230B2 (ja) 2012-12-20 2018-10-10 インセプション ２、 インコーポレイテッド トリアゾロン化合物およびその使用
US9776976B2 (en) * 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379B (zh) * 2022-01-20 2025-06-27 哈尔滨三联药业股份有限公司 海因类化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7712430A (nl) * 1976-11-17 1978-05-19 Montedison Spa Nieuwe fosforzuuresters, afgeleid van 1.2.4- -triazool, met een insecticide, nematocide en acaricide werking en werkwijze ter bereiding daarvan.
CA1106387A (en) * 1976-11-17 1981-08-04 Montedison S.P.A. 1,2,4-triazole intermediate derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
DE10056008A1 (de) * 2000-11-11 2002-05-16 Henkel Kgaa Neue Kupplerkomponenten für Oxidationsfärbemittel
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
MXPA05003830A (es) * 2002-10-11 2005-06-23 Cytokinetics Inc Compuestos, composiciones y metodos.
US20060241157A1 (en) 2003-01-06 2006-10-26 Conner Scott E Heterocyclic ppar modulators
RU2006127575A (ru) * 2004-02-18 2008-03-27 Астразенека Аб (Se) Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
KR20090129406A (ko) * 2007-02-23 2009-12-16 일라이 릴리 앤드 캄파니 퍼옥시좀 증식체 활성화 수용체 조절자
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法

Also Published As

Publication number Publication date
US8822519B2 (en) 2014-09-02
WO2010015212A1 (zh) 2010-02-11
CN102112452A (zh) 2011-06-29
EP2330098A4 (en) 2011-10-26
KR101662592B1 (ko) 2016-10-05
KR20110074971A (ko) 2011-07-05
JP2011529925A (ja) 2011-12-15
CN101643451A (zh) 2010-02-10
CN101643451B (zh) 2013-03-06
EP2330098B1 (en) 2015-04-29
RU2011103231A (ru) 2012-09-20
US20110319458A1 (en) 2011-12-29
EP2330098A1 (en) 2011-06-08
CN102112452B (zh) 2014-05-14
JP5710480B2 (ja) 2015-04-30
RU2522450C2 (ru) 2014-07-10

Similar Documents

Publication Publication Date Title
BRPI0915727A2 (pt) processo para a preparação de compostos nanoparticulados de cobre modificados na superfície, compostos nanoparticulados de cobre modificados na superfície, uso de compostos nanoparticulados de cobre modificados na superfície, processo para a preparação de uma dispersão aquosa, dispersóes aquosas, e, uso de dispersões aquosas.
BRPI1009481A2 (pt) compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
BRPI0917083A2 (pt) compostos com efeito de agitação no recptor de subtipo delta ativado por proliferador de peroxissomo, processo para sua preparação e uso destes
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0905663A2 (pt) "emulsão estável, processo de preparação da emulsão estável e uso emulsão"
BRPI0915728A2 (pt) composição enzimática, processo para preparar a composição, uso da composição enzimática, e, composição detergente.
BRPI0812712A2 (pt) produto, processo para produzir o produto, e, uso do produto
BRPI0819237A2 (pt) folha de material e processo para sua preparação
BRPI0906957A2 (pt) Aerogéis de carbono, processo para a sua preparação e seu uso
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0915092A2 (pt) composição de frutooligossacarídeo, processo para sua produção e uso
BRPI0717695A2 (pt) "composição, uso de uma compsição e processo de preparação de uma composição"
BRPI0920955A2 (pt) processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica
BRPI0810076A2 (pt) Processo para preparar compostos, uso de compostos, composto, e mistura.
BRPI0915856A2 (pt) processo para preparar micropartículas, uso de um auxiliar de processamento, micropartículas, e, composição
BRPI0908252A2 (pt) Processo para preparar um composto, e, uso de um composto
BRPI0908738A2 (pt) composto, medicamento, uso de um composto, e, processo para preparar os compostos
BRPI0913188A2 (pt) moduladores de receptores 5-ht3, métodos de fabricação, e uso dos mesmos
BRPI0911554A2 (pt) Microemulsão, processo para a preparação de uma microemulsão, e, uso da microemulsão.
BRPI0922390A2 (pt) composição aglutinante, processo para a preparação de uma composição aglutinante aquosa, uso do ácido bórico e/ou de pelo menos um sal do ácido bórico, uso de uma composição aglutinante, material de revestimento superficial, adesivo, e, cimento.
BRPI0816115A2 (pt) Suporte de catalisador amorfo, catalisador, processo para a preparação do suporte de catalisador, e, uso de um componente catalicamente ativo e do suporte de catalisador.
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI0912129A2 (pt) materiais cerâmicos de dimensão nanométrica, processo para a sua síntese e respectivas utilizações
BRPI0806897A2 (pt) Processo de obtenção de trans-resveratrol e/ou emodina e composições nutracêuticas contendo os mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL